Vernalis plc: Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

High impact company profile available at BioMarket

Boston Scientific is one of the leading companies in less-invasive medical devices market offering more than 15,000 products in over 45 countries across the world under the four core business groups: cardiovascular, endosurgery, neuromodulation and car

Analysis of Alcon’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

This analysis examines the historical and forecast performance for Chugai in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sale

The Novartis Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

BTG plc: Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

High impact company profile available at BioMarket

High impact company profile available at BioMarket

Somaxon Pharmaceuticals (Somaxon) is a development stage pharmaceutical company engaged in in-licensing and developing proprietary product candidates for the treatment of psychiatry and neurology disorders.

Analysis of Eli Lilly’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

The number of blockbusters continues to increase. The number is set to increase to 112 in 2007. Of the products set to receive FDA approval this year and generate blockbuster status on an annual basis, GSK’s Cervarix, intended for the prevention

The GlaxoSmithKline Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

Flamel Technologies SA: Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

High impact company profile available at BioMarket

Based on an analysis of 43 companies and 1,200+ products, Datamonitor forecasts that pharmaceutical industry ethical sales will increase at a modest 3.2% CAGR 2006 to 2012. However, behind this industry average figure there are strategic segments of th

Illumina is one of the leading companies in genome and genotyping market. The company’s proprietary technology enables conversion of raw sequence data from the human genome into medically relevant information. The January 2007 acquisition of Sole

Introgen Therapeutics (Introgen) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer. The company has been successful in developing a strong portfolio of

Analysis of Schering-Plough’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

The CSL Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

Iomai Corporation: Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

High impact company profile available at BioMarket

Danaher is a diversified technology company engaged in designing, manufacturing and marketing of professional, medical, industrial and consumer products with strong brand names and significant market positions.

The Merger and Acquisition Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the merger and acquisition (M&A) agreements entered into by the worlds leading biopharma companies

The Abbott Labs Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

This analysis examines the historical and forecast performance for Sepracor in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sa

The Actavis Pharma Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

High impact company profile available at BioMarket

Orexigen Therapeutics Inc: Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

High impact company profile available at BioMarket